PT1603544E - Tratamento de problemas intestinais com n-2,3,3-tetrametilbiciclo 2.2.2. heptan-2-amina - Google Patents

Tratamento de problemas intestinais com n-2,3,3-tetrametilbiciclo 2.2.2. heptan-2-amina Download PDF

Info

Publication number
PT1603544E
PT1603544E PT04720110T PT04720110T PT1603544E PT 1603544 E PT1603544 E PT 1603544E PT 04720110 T PT04720110 T PT 04720110T PT 04720110 T PT04720110 T PT 04720110T PT 1603544 E PT1603544 E PT 1603544E
Authority
PT
Portugal
Prior art keywords
tetramethylbicyclo
heptan
formulations
amine
methods
Prior art date
Application number
PT04720110T
Other languages
English (en)
Inventor
John Devane
Original Assignee
Agi Therapeutics Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agi Therapeutics Res Ltd filed Critical Agi Therapeutics Res Ltd
Publication of PT1603544E publication Critical patent/PT1603544E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
PT04720110T 2003-03-14 2004-03-12 Tratamento de problemas intestinais com n-2,3,3-tetrametilbiciclo 2.2.2. heptan-2-amina PT1603544E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45452703P 2003-03-14 2003-03-14

Publications (1)

Publication Number Publication Date
PT1603544E true PT1603544E (pt) 2008-01-22

Family

ID=32990912

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04720110T PT1603544E (pt) 2003-03-14 2004-03-12 Tratamento de problemas intestinais com n-2,3,3-tetrametilbiciclo 2.2.2. heptan-2-amina

Country Status (17)

Country Link
US (1) US20040209961A1 (pt)
EP (1) EP1603544B1 (pt)
JP (1) JP2006520379A (pt)
AT (1) ATE375152T1 (pt)
AU (1) AU2004218899A1 (pt)
CA (1) CA2518385A1 (pt)
CY (1) CY1108042T1 (pt)
DE (1) DE602004009414T2 (pt)
DK (1) DK1603544T3 (pt)
ES (1) ES2294480T3 (pt)
MX (1) MXPA05009640A (pt)
NO (1) NO20054670L (pt)
NZ (1) NZ542260A (pt)
PL (1) PL1603544T3 (pt)
PT (1) PT1603544E (pt)
WO (1) WO2004080446A1 (pt)
ZA (1) ZA200507159B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224284A1 (en) 2004-03-12 2007-09-27 John Devane Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof
US20060182818A1 (en) * 2005-02-17 2006-08-17 Ough Yon D Transdermal patch and treatment for pain and discomfort
US20060182819A1 (en) 2005-02-17 2006-08-17 Ough Yon D Soap scent patch and treatment for muscle spasm and pain
US20070108228A1 (en) * 2005-11-15 2007-05-17 Willam Kleyne Method and apparatus for flushing eyes and skin
US20080207766A1 (en) * 2007-02-27 2008-08-28 Agi Therapeutics Research Ltd. Methods and compositions for treating at least one upper gastrointestinal symptom
US8569381B2 (en) 2008-05-23 2013-10-29 Targacept, Inc. Combination therapy for the management of hypertension
CA3129729A1 (en) * 2009-09-29 2011-04-07 Novartis Ag Dosage regimen of an s1p receptor modulator
US8529914B2 (en) 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
KR102354954B1 (ko) 2016-04-04 2022-01-24 오메자 엘엘씨 어유 국소 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034079A (en) * 1997-08-11 2000-03-07 University Of South Florida Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
BR9812615A (pt) * 1997-10-03 2000-08-01 Cary Medical Corp Composições farmacêutica para tratar vìcio de tabaco ou vìcio de nicotina, para aliviar os sintomas da abstinência de nicotina ou para facilitar a cessação de fumar, para tratar vìcio de cocaìna e efeitos da abstinência associados, para tratar dependência alcoólica e efeitos da abstinência associados, e, processos para tratar vìcio de tabaco ou vìcio de nicotina, para aliviar os sintomas de abstinência de nicotina ou para facilitar a cessação de fumar, para tratar vìcio de cocaìna e efeitos da abstinência associados e, para tratar dependência alcoólica e efeitos da abstinência associados
AR016212A1 (es) * 1998-04-28 2001-06-20 Astra Ab Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas
US6121289A (en) * 1998-10-09 2000-09-19 Theramax, Inc. Method for enhanced brain delivery of nicotinic antagonist
CA2380391A1 (en) * 1998-12-07 2000-06-15 J. Miranda Transdermal patch for delivering volatile liquid drugs
US6734215B2 (en) * 1998-12-16 2004-05-11 University Of South Florida Exo-S-mecamylamine formulation and use in treatment
JP2002532393A (ja) * 1998-12-16 2002-10-02 ユニヴァーシティー オブ サウス フロリダ エキソ−ｒ−メカミラミン製剤および治療におけるその使用
AU3104301A (en) * 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
US6780871B2 (en) * 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders

Also Published As

Publication number Publication date
EP1603544B1 (en) 2007-10-10
NO20054670D0 (no) 2005-10-11
DK1603544T3 (da) 2008-01-14
US20040209961A1 (en) 2004-10-21
WO2004080446B1 (en) 2004-12-09
CY1108042T1 (el) 2013-09-04
CA2518385A1 (en) 2004-09-23
NO20054670L (no) 2005-12-13
DE602004009414T2 (de) 2008-07-24
MXPA05009640A (es) 2005-10-26
AU2004218899A1 (en) 2004-09-23
EP1603544A1 (en) 2005-12-14
PL1603544T3 (pl) 2008-03-31
NZ542260A (en) 2009-03-31
JP2006520379A (ja) 2006-09-07
ATE375152T1 (de) 2007-10-15
ES2294480T3 (es) 2008-04-01
DE602004009414D1 (de) 2007-11-22
ZA200507159B (en) 2008-03-26
WO2004080446A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
MXPA04008772A (es) Composiciones de clorhidrato de naltrexona.
NO20054670L (no) Behandling av intestinale tilstander med N-2,3,3-tetrametylbisyklo[2.2.1]-heptan-2-amid
SG150533A1 (en) 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
EP1628530A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SEPSIA
EP1583603A4 (en) WATER-SOLUBLE PRODUCTS AND METHODS OF MAKING AND USING THE SAME
MX249034B (es) Amidinas de tiofeno novedosas, composiciones de las mismas, y metodos para tratar enfermedades y condiciones mediadas por el complemento.
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
WO2003105840A3 (en) SPHINGOSINE KINASE INHIBITORS
IL158181A0 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
EP1711197A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES OR DISORDERS
WO2003103571A3 (en) VACCINES AGAINST FLAVIVIRUSES
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
NO20054346D0 (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
EP1575503A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF INFECTIONS
GB0324523D0 (en) Compositions and methods of treatment
AU2003243381A8 (en) Variants of antithrombin iii
UA85187C2 (en) 2-aminobenzoyl derivatives
MXPA05005574A (es) Compuestos calciliticos.
WO2004096121A3 (en) Compositions and methods for preventing infection
AU2003275069A8 (en) Compositions and methods for preventing infection
HK1079693A1 (en) Compositions for treating and/or preventing pollenosis
DE60220504D1 (en) Tryptasehemmer
GB0205327D0 (en) compounds